484 related articles for article (PubMed ID: 21175794)
1. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
2. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
Ibrahim M; Gomaa W; Ibrahim Y; El Hadad H; Shatat M; Aleem AA; Essawy M; Fouad YM
J Gastrointestin Liver Dis; 2010 Dec; 19(4):387-92. PubMed ID: 21188329
[TBL] [Abstract][Full Text] [Related]
6. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
7. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
8. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
9. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
10. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
[TBL] [Abstract][Full Text] [Related]
14. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.
Shin SR; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
J Gastroenterol Hepatol; 2010 May; 25(5):957-63. PubMed ID: 20546450
[TBL] [Abstract][Full Text] [Related]
16. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA
AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550
[TBL] [Abstract][Full Text] [Related]
17. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Atsukawa M; Tsubota A; Kondo C; Itokawa N; Narahara Y; Nakatsuka K; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Kanazawa H; Sakamoto C
J Gastroenterol Hepatol; 2013 Jan; 28(1):51-6. PubMed ID: 22989264
[TBL] [Abstract][Full Text] [Related]
18. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
20. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Knop V; Teuber G; Klinker H; Möller B; Rasenack J; Hinrichsen H; Gerlach T; Spengler U; Buggisch P; Neumann K; Sarrazin C; Zeuzem S; Berg T
Ann Hepatol; 2013; 12(2):190-8. PubMed ID: 23396729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
